Centessa IPO Presentation Deck
SerpinPC: Potential First-in-Class Rebalancing Agent with
Unique MoA
MOA OVERVIEW
• Supported by human genetics: coinheritance of
Factor V Leiden mutation (which mimics effect of
reduced APC) with severe hemophilia produces
mild bleeding phenotype
• Innovative pharmacology built on alpha-1-
antitrypsin scaffold to produce desired PK and
low immunogenicity
• Designed to 'mop-up' pre-existing APC by
Ecovalent mechanism thereby prolonging activity
of prothrombinase formed during initiation stage
of hemostasis
• Designed to directly increase amount of thrombin
generated at site of tissue damage
. Modest rate of inhibition intended to allow newly
formed APC to attenuate thrombin generation
• No interaction with protein C, thereby leaving
cytoprotective signaling through Endothelial
Protein C receptor intact
SERPINPC'S MODE OF ACTION
SerpinPC-
Prothrombin
Intrinsic
Tenase
APC
Prothrombinase
Extrinsic
Tenase
Protein C
Feedback Loop
Thrombin
Apcintex
CENTESSA 18View entire presentation